SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck reports sustained tumor control with pimicotinib over two years

Merck says its Phase 3 study showed sustained tumor control with pimicotinib over two years.

MERCK

Related stories